

OUTLOOK
Traditional Asian
medicine

nature

PR

THE INTERNATIONAL WEEKLY JOURNAL OF SCIENCE

RECEIVED

DEC 29 2011

UNIVERSITY MICROFILMS

ONE YEAR

TEN STORIES

DO NOT REMOVE FROM
CURRENT PERIODICALS
ROOM

Genome & Co. v. Univ. of Chicago
PGR2019-00002
UNIV. CHICAGO EX. 2036

The newsmakers of the year **PAGE 437**

HIGGS BOSON

**REBOOTING
PHYSICS**
Particle could tie string

NEWS & VIEWS

**CREAM OF
THE CROP**
Editors' pick of 2011's

CALENDAR

**EVENTS
DIRECTORY 2012**
Your guide to global scientific

NATURE.COM/NATU
22/29 December 2011

\$10.00US \$12.99CA



**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

CONTENTS

22/29 December 2011 / Vol 480 / Issue No 7378

2011 IN REVIEW

EDITORIAL

- 414 **Ten for 2011**
Capturing the characters of the year

NEWS

- 426 **2011 in review**
From scandals to fallout and all points between
- 430 **Images of the year**

FEATURES

- 437 **Nature's 10**
Who were the people who made a mark on the past 12 months?



Cover and illustrations by Carl DeTorres

COMMENT

- 447 **The new history**
Philip Ball
The major events of 2011 were driven by complexity as well as social media and globalization

NEWS & VIEWS

- 468 **Editors' choice**
A look back at some of the highlights from this year's News & Views

 nature.com/2011

THIS WEEK

EDITORIALS

- 413 **POLICY**
The morning after
The US government was wrong to overrule recommendations on Plan B
- 413 **ENVIRONMENT**
Defend the Amazon
Brazil's attempts to reform forest protection must be reworked

WORLD VIEW

- 415 **Particle physics is at a turning point**
Gordon Kane
The putative discovery of the Higgs boson is a boon for string theorists

RESEARCH HIGHLIGHTS

- 416 **SELECTIONS FROM THE SCIENTIFIC LITERATURE**



Mercury's magnetosphere / Egg counts / Bacterial microtubules / Why frogs make music / Lost *Hox* genes / Owning the world / Neanderthals not up to sniff

SEVEN DAYS

- 418 **THE NEWS IN BRIEF**
Fukushima finally in shutdown / The world's tiniest tetrapod / Vote on

NEWS IN FOCUS

- 421 **BIOSAFETY**
Altered bird-flu virus raises questions about lab security
- 423 **POLICY**
US budget paves the way for new NIH centre



424 **ANIMAL RESEARCH**
Report spells out tough criteria for NIH-funded chimp research

425 **POLICY**
US integrity rules edge closer to reality

CAREERS

- 575 **AWARDS**
Conscientious counsellors
Nature's 2011 mentoring awards go Parisienne
- 576 **COLUMN**
Testing the waters
Postdocs and industry do mix, say Christopher Tsang and Michael Fisher

nature events

Your guide to global scientific events

COMMENT

- 449 **SCIENCE PUBLISHING**
The paper is not sacred
Adam Marcus & Ivan Oransky
The rise in retractions this year argues for the broadening of peer review

BOOKS & ARTS

- 451 **TECHNOLOGY**
Rise of the e-book
Carl Zimmer
- 452 **FOOD SCIENCE**
With pipette and ladle
Harold McGee
- 453 **Q&A**
The snowflake designer
Physicist Kenneth Libbrecht takes the study of snowflakes to extremes
- 455 **IN RETROSPECT**
On the Six-Cornered Snowflake
Philip Ball

CORRESPONDENCE

- 457 Leonardo da Vinci's physics / Europe's threatened vultures / The first cells

OBITUARY

- 458 **Lynn Margulis (1938–2011)**
James A Lake

FUTURES

CONTENTS

22/29 December 2011 / Vol 480 / Issue No 7378

RESEARCH

NEW ONLINE

459 Papers published this week at nature.com

NEWS & VIEWS

460 PLANETARY SCIENCE

The ultimate fate of planets

Discovery of a planetary system in orbit around an evolved star

Eliza M R Kempton **SEE LETTER P.496**

461 ECOLOGY

Bleak future for amphibians

Predicting the distribution of threats to amphibians

Ross A Alford **SEE LETTER P.516**

MATERIALS SCIENCE

Take charge

Repackaging organic semiconductors to be more flexible. **PAGE 504**



463 ATOMIC PHYSICS

When ultracold is not cold enough

How to cool quantum atomic gases in optical lattices

Gretchen K Campbell **SEE LETTER P.500**

463 PSYCHOLOGY

Who needs a leader?

The dynamics of joint improvisation

Sadaf Shadan

465 CONDENSED-MATTER PHYSICS

A fresh twist on shrinking materials

Negative thermal expansion in scandium trifluoride

J Paul Attfield

466 PHYSIOLOGY

On time metabolism

Glucocorticoid signalling by the clock

Joseph Bass **SEE LETTER P.552**

REVIEWS

471 ORGANIC CHEMISTRY Rethinking amide bond synthesis

V R Pattabiraman & J W Bode

480 CANCER Cancer immunotherapy comes of age

I Mellman, G Coukos & G Dranoff

ARTICLE

490 GENOMICS DNA-binding factors shape the mouse methylome at distal regulatory regions

M B Stadler et al.

LETTERS

496 ASTRONOMY A compact system of small planets around a former red-giant star

S Charpinet et al. **SEE N&V P.460**

500 PHYSICS Orbital excitation blockade and algorithmic cooling in quantum gases

W S Bakr et al. **SEE N&V P.463**

504 MATERIALS SCIENCE Tuning charge transport in solution-sheared organic semiconductors using lattice strain

G Giri et al.

509 CLIMATE SCIENCE Forcing of wet phases in southeast Africa over the past 17,000 years

E Schefuß, H Kuhlmann, G Mollenhauer, M Prange & J Pätzold

513 PALAEOLOGY Lowland-upland migration of sauropod dinosaurs during the Late Jurassic epoch

H C Fricke, J Honecrotch & M E Hoerner

516 ECOLOGY Additive threats from pathogens, climate and land-use change for global amphibian diversity

C Hof, M B Araújo, W Jetz & C Rahbek **SEE N&V P.461**

520 GENOMICS The *Medicago* genome provides insight into the evolution of rhizobial symbioses

N D Young et al.

525 NEUROBIOLOGY Natural polymorphisms in *C. elegans* HECW-1 E3 ligase affect pathogen avoidance behaviour

H C Chang, J Paek & D H Kim

530 VIROLOGY Adherens junction protein nectin-4 is the epithelial receptor for

534 PARASITOLOGY Basigin is a receptor essential for erythrocyte invasion by *Plasmodium falciparum*

C Crosnier et al.

538 IMMUNOLOGY Response to self antigen imprints regulatory memory in tissues

M D Rosenblum et al.

543 CELL BIOLOGY Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease

P Koch et al.

547 STEM CELLS Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease

S Kriks et al.

552 METABOLISM Cryptochromes mediate rhythmic repression of the glucocorticoid receptor

K A Lamia et al. **SEE N&V P.466**

557 BIOCHEMISTRY GlcNAcylation of histone H2B facilitates its monoubiquitination

R Fujiki et al.

561 MOLECULAR BIOLOGY An equilibrium-dependent retroviral mRNA switch regulates translational recoding

B Houck-Loomis et al.

565 STRUCTURAL BIOLOGY Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket

R Nakashima, K Sakurai, S Yamasaki, K Nishino & A Yamaguchi

570 BIOCHEMISTRY Intermediates in the transformation of phosphonates to phosphate by bacteria

S S Kamat, H J Williams & F M Raushel

GENOMICS

Top model

The genome of barrel clover, green manure and model legume. **PAGE 520**



nature

22/29 December 2011 / Vol 480 / Issue No. 7378

EDITORIAL

LONDON, MUNICH, WASHINGTON DC, NEW YORK,
BOSTON, PARIS, SAN FRANCISCO, TOKYO

nature@nature.com

EDITOR-IN-CHIEF: Philip Campbell
MANAGING EDITOR: Nick CampbellPUBLISHING EXECUTIVE EDITOR: Maxine Clarke EXECUTIVE EDITOR: Véronique Kiermer
CHIEF MAGAZINE EDITOR: Tim Appenzeller

THIS WEEK/NEWS/FEATURES: Alison Abbott, David Adam, Ananyo Bhattacharya, Geoff Brumfiel, Declan Butler, Ewen Callaway, Erika Check Hayden, Daniel Cressey, David Cyranoski, Natasha Gilbert, Eric Hand, Heidi Ledford, Corie Lok, Brendan Maher, Emma Marris, Richard Monastersky, Brian Owens, Helen Pearson, Mark Peplow, Eugenie Samuel Reich, Ivan Semeniuk, Quirin Schiermeier, Jeff Tollerson, Richard Van Noorden, Meredith Wadman, M Mitchell Waldrop COMMENT: Sara Abdulla, Joanne Baker, Rosalind Cotter, Barbara Kiser, Alison McCook, Lucy Odling-Smee, Sarah Tomlin NATURE PODCAST/VIDEO: Adam Rutherford, Eric Olson, Kerri Smith, Charlotte Stoddart NEWS AND VIEWS: Sadaf Shadan, Ana Lopes, Andrew Mitchinson, Cesar Sanchez RESEARCH: Ritu Dhand, Karl Ziemelis, Francesca Cesari, I-han Chou, Tanguy Chouard, Rosamund Daw, Alex Eccleston, Angela Eggleston, Joshua Finkelstein, Henry Gee, Patrick Goymier, Noah Gray, Marie-Thérèse Heemels, Magdalena Helmer, Karen Howell, Claudia Lupp, Barbara Marte, Andrew Mitchinson, Alberto Moscatelli, Juliane Mössinger, Deepa Nath, Leslie Sage, Magdalena Skipper, Clare Thomas, John VanDecar, Liesbeth Venema, Ursula Weiss, Michael White INSIGHTS/REVIEWS/PERSPECTIVES: Ursula Weiss CAREERS: Gene Russo, Karen Kaplan TECHNOLOGY FEATURES: Monya Baker FUTURES: Henry Gee SUPPLEMENTS: Herb Brody, Michelle Grayson, Tony Scully SUBEDITORS: Colin Sullivan, Sarah Archibald, Nicola Bailey, Anne Blewett, Nicolas Faget, Isobel Flanagan, Paul Fletcher, Afsaneh Gray, Dinah Loon, Anna Novitzky, Yukie Ozawa, Katherine Perry, David Price, Jenny Rooke, Chris Simms, David Winters, Anna York PRODUCTION: Jenny Henderson, Gemma Carder, Leonora Dawson-Bowling, Dan Foley, Stewart Fraser, Susan Gray, Simon Gribbin, James McQuat, Emilia Orvis, Yvonne Strong, Robert Sullivan, Roberta Tarran, Charles Wenz ART AND DESIGN: Kelly Buckheit Krause, Wesley Fernandes, Madeline Hutchinson, Barbara Izdebska, Paul Jackman, Jasiel Krzysztofiak, Annthea Lewis, Nik Spencer, Claire Welsh, Mark Wood JAPAN EDITION: Mika Nakano, Akemi Tanaka, Mitsuyo Utsugi PRESS OFFICE: Ruth Francis, Neda Afsarmanesh, Lisa Boucher, Rachel Twinn, Rebecca Walton ADMINISTRATION: Paul Sng, Helen Anthony, Liz Bankes, Roseann Campbell, Faye Fornasier, Amy Invernizzi, Diane Kempinski, Hazel Mayhew, Katie McGoldrick, Jenny Meyer, Rina Nozawa, Kenneth Simpson, Claire Smith, Tanya Szwarnowska

PUBLISHING

LONDON

feedback@nature.com

MANAGING DIRECTOR & PUBLISHER: Steven Inchcoombe

ASSISTANT PUBLISHER: Arash Hejazi

PUBLISHING PROJECT MANAGER: Christian Manto

PROJECT MANAGER: Helen Anthony

TOKYO

feedback@natureasia.com

PUBLISHING DIRECTOR — ASIA-PACIFIC: David Swinbanks

ASSOCIATE DIRECTOR — ASIA-PACIFIC: Antoine E Bocquet

DISPLAY ADVERTISING, SPONSORSHIP & NATUREJOBS

GLOBAL HEAD: Andrew Douglas

a.douglas@nature.com

DISPLAY ADVERTISING AND SPONSORSHIP

GLOBAL HEAD: Gerard Preston

g.preston@nature.com

ASSISTANT SPONSORSHIP MANAGER: Reya Silao Tel: +44 (0)20 7843 4977 (r.silao@nature.com)

EUROPE/REST OF WORLD display@nature.com Tel: +44 (0)20 7843 4960

GERMANY/SWITZERLAND/AUSTRIA: Sabine Hugi-Fürst Tel: +41 52761 3386

UK/IRELAND/SCANDINAVIA/SPAIN/PORTUGAL: Evelina Rubio Hakansson Tel: +44 (0)20 7843 4079

FRANCE/BELGIUM/THE NETHERLANDS/LUXEMBOURG/ITALY/OTHER EUROPE: Nicola Wright

Tel: +44 (0)20 7843 4959

NORTH AMERICA

display@natureny.com

NEW ENGLAND/ EASTERN CANADA: Sheila Reardon Tel: +1 617 494 4900

NEW YORK/MID-ATLANTIC/SOUTHEAST: Jim Breault Tel: +1 212 726 9334

MIDWEST: Mike Rossi Tel: +1 212 726 9255

WEST COAST/ WESTERN CANADA: George Lui Tel: +1 415 781 3804

WEST COAST NORTH: Kayla McCutchan Tel: +1 415 403 9038

ASIA-PACIFIC

display@natureasia.com

ASIA-PACIFIC HEAD: Kate Yoneyama

JAPAN: Ken Mikami Tel: +81 3 3267 8765

GREATER CHINA/SINGAPORE: Gloria To Tel: +852 2811 7191

INDIA: Vikas Chawla Tel: +91 124 288 1057

SPONSORSHIP

BUSINESS DEVELOPMENT MANAGER: David Bagshaw Tel: +1 212 726 9215 BUSINESS DEVELOPMENT

MANAGER: Patrick Murphy Tel: +1 617 475 9216

NATUREJOBS

naturejobs@nature.com

EUROPEAN HEAD OFFICE, LONDON: Tel: +44 (0)20 7843 4961

EUROPEAN SALES MANAGER: Nils Moeller (n.moeller@nature.com) BUSINESS DEVELOPMENT MANAGER,

MIDDLE EAST: Jon Giuliani (j.giuliani@nature.com) ADVERTISING PRODUCTION MANAGER: Stephen

Russell NATUREJOBS ONLINE PRODUCTION: Dennis Chu

US HEAD OFFICE, NEW YORK: naturejobs@natureny.com US SALES MANAGER: Ken Finnegan

JAPAN HEAD OFFICE, TOKYO: Tel: +81 3 3267 8765 ASIA-PACIFIC HEAD: Kate Yoneyama

ASIA-PACIFIC SALES & BUSINESS DEVELOPMENT MANAGER: Yuki Fujiwara BUSINESS DEVELOPMENT

MANAGER, GREATER CHINA, SINGAPORE: Gloria To Tel: +852 2811 7191

INDIA: Vikas Chawla Tel: +91 1242881057 (v.chawla@nature.com)

MARKETING & SUBSCRIPTIONS

USA/CANADA/LATIN AMERICA

Tel: (USA/Canada)+1 866 363 7860; (outside USA/Canada) +1 212 726 9223

MARKETING: Sara Girard FULFILLMENT: Karen Dawson

JAPAN/CHINA/KOREA

Tel: +81 3 3267 8751 MARKETING/PRODUCTION: Keiko Ikeda, Takeshi Murakami

EUROPE/REST OF WORLD

Tel: +44 (0)1256 329242

MARKETING: Elena Woodstock, Marcus Parker, Hannah Phipps FULFILLMENT: Jean Burrows

INDIA

Tel: +91 124 2881053/54

HEAD OF BUSINESS DEVELOPMENT, INDIA: Debashish Brahmachari MARKETING: Harpal Singh Gill

ANNUAL SUBSCRIPTIONS (UK/Europe, including post and packing)

FULL RATE: £1,400

PERSONAL RATES: UK £135; Europe €209; Rest of World £210

STUDENT RATES: UK £79; Europe €122; Rest of World £125

Individual rates apply to payments by personal cheque or credit card. Back issues: £20.00.

ANNUAL SUBSCRIPTIONS (USA, including post and packing)

INSTITUTIONAL/CORPORATE RATE: \$2,730 ; PERSONAL RATE: \$199; STUDENT RATE: \$99;

POSTDOC RATE: \$119

Printed in USA. Individual rates available only to subscribers paying by personal check or credit

card. Orders for student/postdoc subscriptions must be accompanied by a copy of student

ID. Rates apply to USA, Canada, Mexico/Central & South America. Add 7% GST tax in Canada

(Canadian GST number 140911595). BACK ISSUES: US\$20.00.

ANNUAL SUBSCRIPTIONS (Asia, including post and packing)

JAPAN: 年間購読料金: Natureのみ 437,800円 +21,890円(消費税)=459,690円(合計)

Nature + Nature Digest 466,550円 +23,328円(消費税)=489,878円(合計)

お問い合わせ: 日本出版貿易株式会社 国内営業 1部

〒101-0064 東京都千代田区猿樂町1-2-1 Tel: 03-3292-3767 Fax: 03-3292-8766

個人/学生購読について

NPG ネイチャー アジア・パシフィック フルフィルメント & カスタマーサービス

〒162-0843 東京都新宿区市谷田町2-37 千代田ビル Tel: 03-3267-8759 Fax: 03-3267-8752

CHINA: www.natureasia.com/ch/subscribe; KOREA: www.natureasia.com/korea/subscribe

NATURE ONLINE

WWW.NATURE.COM/NATURE

CHIEF TECHNOLOGY OFFICER: Howard Ratner ASSOCIATE DIRECTOR, NATURE.COM: Daniel Pollock

PLATFORM DEVELOPMENT: Jeremy Macdonald WEB PRODUCTION: Alexander Thurrell, Deborah

Anthony WEB DESIGN: Juan-Carlos Sobrino, Luke Stavenhagen PLATFORM INTERFACES: Amanda Ward

SITE LICENCES, FULFILLMENT & CUSTOMER SERVICES

SITE LICENCES: npg.nature.com/libraries

feedback@nature.com

CHIEF OPERATIONS OFFICER: John Carroll ASSOCIATE DIRECTOR OF OPERATIONS: Dominic Pettit

CUSTOMER SERVICE: Gerald Coppin ORDER PROCESSING OPERATIONS: Steve Poulter

NATURE PUBLISHING GROUP OFFICES

LONDON: The Macmillan Building, 4 Crinan Street, London N1 9XW Tel: +44 (0)20 7833

4000 Fax: +44 (0)20 7843 4596/7

BASINGSTOKE: Nature Publishing Group, Subscriptions, Brunel Road, Basingstoke, Hants

RG21 6XS, UK Tel: +44 (0)1256 329242

WASHINGTON DC: 968 National Press Building, 529 14th St NW, Washington DC 20045-

1938 Tel: +1 202 737 2355

NEW YORK: 75 Varick St, 9th Floor, New York, NY 10013-1917 Tel: +1 212 726 9200

BOSTON: 25 First Street, Suite 104, Cambridge, MA 02141 Tel: +1 617 475 9275

SAN FRANCISCO: 225 Bush Street, Suite 1453, San Francisco, CA 94104 Tel: +1 415

403 9027

MUNICH: Nymphenburger Strasse 14, D-80335 München Tel: +49 89 549057-13

PARIS: Moulin de Malicorne, Sainte Maure de Touraine, Paris 37800 Tel: +33 2 47 35 72 15

TOKYO: Chiyoda Building, 2-37 Ichigaya Tamachi, Shinjuku-ku, Tokyo 162-0843 Tel: +81

3 3267 8751

INDIA: Nature Publishing Group, 3A, 4th Floor, DLF Corporate Park, Gurgaon 122002 Tel:

+91 124 2881053/54

Nature® (ISSN 0028-0836) is published by Nature Publishing Group, a division of Macmillan Publishers Ltd (The Macmillan Building, 4 Crinan Street, London N19XW). Registered as a newspaper at the British Post Office. North and South American orders to subscriptions@natureny.com (Tel: +1 866 363 7860). Other orders to subscriptions@nature.com (Tel: +44 (0)1256 329242; Fax +44 (0)1256 812358). Authorization to photocopy material for internal or personal use, or internal or personal use of specific clients, is granted by Nature to libraries and others registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided the relevant copyright fee is paid direct to CCC, 222 Rosewood Drive, Danvers MA 01923, USA. Identification code for Nature: 0028-0836/03. CPC PUB AGREEMENT #40032744. In the US, Nature (ISSN 0028-0836) is published weekly on Thursday, except the last week in December by Nature Publishing Group, 75 Varick St, 9th Fl, New York NY 10013-1917, USA. US Periodicals postage paid at New York NY, and additional mailing post offices. US POSTMASTER: send address changes to Nature, Subscription Dept, 75 Varick St, 9th Fl, New York NY 10013-1917, USA. Published in Japan by NPG Nature Asia-Pacific, Chiyoda Building, 2-37 Ichigayatamachi, Shinjuku-ku, Tokyo 162-0843, Japan. © 2011 Macmillan Publishers Limited. All rights reserved.

REVIEW

doi:10.1038/nature10673

Cancer immunotherapy comes of age

Ira Mellman¹, George Coukos² & Glenn Dranoff³

Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.

The passive transfer of anticancer monoclonal antibodies and donor T cells in the context of allogeneic bone marrow transplantation are effective treatments for a variety of haematological and solid malignancies¹. Although not always thought of as 'immunotherapy', the success of these biotherapeutics probably reflects the ability of the donor cells or antibodies to induce an immediate immune reaction against the cancer, bypassing the requirement to activate endogenous immunity. These immune treatments have been well-established in oncology for several decades, and continued advances in antibody and T-cell engineering should further enhance their clinical impact in the years to come (Box 1).

In contrast to these passive immunotherapy strategies, the active stimulation of specific and durable antitumour immunity has proved elusive. In 1891, William Coley, a young New York surgeon, began intratumoural injections of live or inactivated *Streptococcus pyogenes* and *Serratia marcescens* in an effort to reproduce the spontaneous remissions of sarcomas observed in rare-cancer patients who had developed erysipelas². Given Elie Metchnikoff's contemporaneous work demonstrating the immune system's ability to cause inflammation and destroy invading bacteria, 'Coley's toxins' made sense by acting to stimulate antibacterial phagocytes that might kill bystander tumour cells. Some significant responses were recorded over the ensuing 40 years, but successes were sporadic, difficult to reproduce and not obtained in a scientifically rigorous fashion. Superficial bladder cancer was one notable exception, for which the intravesical injection of live bacillus Calmette-Guérin after surgical resection was shown to prolong patient survival³. Other than this particular clinical setting, the approach was never embraced by oncologists who continued to rely on surgery and, increasingly, on effective new methods, such as radiation therapy and ultimately chemotherapy. Coley's strategy was further discounted due to the very real risks associated with the administration of infectious, or at least pyrogenic, agents to already weakened cancer patients; this is ironic given the trauma associated with the treatments that did come into common use. Thus began the history of cancer immunotherapy. Before continuing, however, it is useful to summarize what must happen to elicit a protective immune response to cancer, and why overcoming these barriers has been so difficult.

Generating anticancer immunity is a multistep challenge

Based on our current understanding of the immune response, there are three distinct steps that must be achieved, either spontaneously or therapeutically, to mount effective antitumour immunity (Fig. 1). To

BOX 1

Established immune treatments

Nine monoclonal antibodies targeting six cancer-associated proteins (Her2/neu, EGFR, VEGF, CD20, CD52 and CD33) are approved for the treatment of solid and haematological malignancies. In addition to antagonizing oncogenic pathways, these biotherapeutics may act by opsonizing tumour cells and triggering their death or removal by antibody-dependent cellular cytotoxicity or phagocytosis⁹⁴. Ongoing investigations in murine models and patients raise the possibility that they may also stimulate adaptive immune responses in some settings⁹⁵. Recently, the successful conjugation of toxins to antibodies has been achieved, and these have induced a clinical response in patients who are refractory to the naked antibody⁹⁶. The concurrent administration of immunostimulatory cytokines such as IL-2 and GM-CSF may also enhance the efficacy of antibody therapy.

Allogeneic bone marrow transplantation and the infusion of donor lymphocytes can be a highly effective therapy for some leukaemias and lymphomas²⁴. The graft-versus-leukaemia effects involve the direct killing of tumour cells by donor lymphocytes, together with the subsequent induction of broader innate and adaptive reactions. On the basis of these clinical benefits, many groups are exploring the use of adoptive T-cell therapy in the autologous setting. Promising strategies include the use of lymphodepletion before T-cell infusion, and the engineering of new T-cell specificities with CARs⁹⁷.

Other immune treatments that have received the FDA approval include recombinant cytokines, such as IL-2 (Proleukin), which is used for melanoma and renal cell cancer. Response rates are low (~15%) and the significant risk of serious systemic inflammation requires administration as an in-patient. Interferon- α is another agent that gained approval for 'immunological cancers' (that is, melanoma or renal cell cancer). Although also associated with low response rates and high-dose toxicity, a small subset of melanoma patients, who are also predisposed to autoimmunity, has been shown to exhibit an impressive survival response⁹⁸. It has been, however, difficult to pre-identify these patients, which limits the use of the approach. Yet, when seen, responses are durable, suggesting they reflect active antitumour immunity.

¹Genentech, 1 DNA Way, South San Francisco, California 94080, USA. ²Ovarian Cancer Research Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

³Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.




Figure
Unders
suggest
present
protect
bed. A
associa
from d
antiger
molecu
presen
dendri
if no s
leading
node, i
of den
co-stir
interac
protect
with P
forma
the lyr
defenc
that o
L2 on
suppr
hypox
infil

initia
tumo
a the
many
muta
exam
with
toler
assoc
cells
allow
oppe
of tr
thera
(TLF
CD4
(for
resul
tumo

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.